henhaobio
Sign in

bioRxivImmunologyPreprint

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains

C. Chen, J. W. Saville, M. M. Marti, A. Schaefer, M. H. Cheng, D. Mannar, X. Zhu, A. M. Berezuk, A. Banerjee, M. D. Sobolewski, A. Kim, B. R. Treat, P. M. Da Silva Castanha, N. Enick, K. D. McCormick, X. Liu, C. Adams, M. G. Hines, Z. Sun, W. Chen, J. L. Jacobs, S. M. Barratt-Boyes, J. W. Mellors, R. S. Baric, I. Bahar, , W. Li

PDFDOI

Abstract

The emergence of SARS-CoV-2 variants of concern (VOCs) requires the development of next-generation biologics that are effective against a variety of strains of the virus. Herein, we characterize a human VH domain, F6, which we generated by sequentially panning large phage displayed VH libraries against receptor binding domains (RBDs) containing VOC mutations. Cryo-EM analyses reveal that F6 has a unique binding mode that spans a broad surface of the RBD and involves the antibody framework region. Attachment of an Fc region to a fusion of F6 and ab8, a previously characterized VH domain, resulted in a construct (F6-ab8-Fc) that neutralized Omicron pseudoviruses with a half-maximal neutralizing concentration (IC50) of 4.8 nM in vitro. Additionally, prophylactic treatment using F6-ab8-Fc reduced live Beta (B.1.351) variant viral titers in the lungs of a mouse model. Our results provide a new potential therapeutic against SARS-CoV-2 VOCs - including the recently emerged Omicron variant - and highlight a vulnerable epitope within the spike protein RBD that may be exploited to achieve broad protection against circulating variants.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.